Homocysteine and bone loss in epilepsy

Area of Science:

• Neurology
• Metabolic Bone Disease
• Nutritional Science

Background:

• Fracture incidence in epilepsy patients is double that of the general population.
• While Vitamin D is studied, other metabolic factors like homocysteine may contribute to bone density loss in epilepsy.
• Anti-epileptic drugs (AEDs) are known to increase serum homocysteine (s-Hcy) by reducing folate levels.

Purpose of the Study:

• To investigate the relationship between AEDs, homocysteine levels, bone mineral density (BMD), and fracture history in epilepsy patients.
• To identify predictors of bone density and fracture risk in individuals with epilepsy on AEDs.

Main Methods:

• Cross-sectional study analyzing biochemical markers, BMD (DEXA T-scores), fracture history, and medication use in epilepsy patients.
• One-way ANOVA and regression analyses were employed to determine associations and predictors.

Main Results:

• Elevated s-Hcy levels were confirmed in AED users, with phenytoin monotherapy showing significantly higher levels.
• Homocysteine, fracture history, duration of AED use, and ethnicity predicted spine T-scores.
• Enzyme-inducing AEDs negatively predicted spine BMD, while phenytoin positively predicted it. Lamotrigine negatively predicted spine T-scores.
• Nutritional supplementation was associated with 25% lower s-Hcy levels.

Conclusions:

• Elevated homocysteine, influenced by AEDs, is linked to reduced bone density and increased fracture risk in epilepsy.
• Specific AEDs and patient factors (ethnicity, BMI, menopause) influence bone health outcomes.
• Nutritional supplementation is a crucial intervention for managing homocysteine and potentially mitigating bone loss in epilepsy care.